|
Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Gilead Sciences; Roche; Takeda |
Consulting or Advisory Role - Gilead Sciences; Roche |
Travel, Accommodations, Expenses - Abbvie |
|
|
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche |
Research Funding - Acerta Pharma; BeiGene; Epizyme; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Genmab; Janssen; Kite, a Gilead company |
Speakers' Bureau - Abbvie; Janssen |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/Merck; Genmab; Janssen |
|
|
Consulting or Advisory Role - Abbvie; Celgene; Genmab; Incyte; Regeneron; Roche/Genentech; Takeda; Y-mAbs Therapeutics |
Research Funding - SERVIER (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Celgene |
|
|
Stock and Other Ownership Interests - OVIBIO |
Consulting or Advisory Role - OVIBIO |
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - BeiGene; Janssen Oncology; Kite/Gilead |
Travel, Accommodations, Expenses - Kite, a Gilead company |
|
|
Honoraria - Abbvie; Astellas Pharma; Janssen; MSD; Novartis; Otsuka |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda; Yuhan |
Speakers' Bureau - IMBdx; Janssen Research & Development; Takeda |
Research Funding - AstraZeneca |
(OPTIONAL) Uncompensated Relationships - AstraZeneca/MedImmune; Boryung; Novartis; Roche/Genentech |
|
|
Consulting or Advisory Role - Takeda |
Travel, Accommodations, Expenses - Abbvie; Daiichi Sankyo; Jazz Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb; Kite, a Gilead company; Pharmacyclics/Janssen; Seagen; Takeda |
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genmab; Seagen |
Speakers' Bureau - Kite, a Gilead company; Seagen |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Cell Medica (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Pfizer (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Trillium Therapeutics (Inst); Viracta Therapeutics (Inst); Viracta Therapeutics (Inst) |
Travel, Accommodations, Expenses - Seagen; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Roche; Sanofi; Takeda |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Novartis; Takeda |
Speakers' Bureau - Takeda |
Travel, Accommodations, Expenses - Kite/Gilead |
Other Relationship - Celgene; Gilead Sciences; Roche; Sanofi; Takeda |
|
|
Consulting or Advisory Role - Abbvie; Genmab; Janssen; Roche; Takeda |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Genmab (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst) |
|
|
|
Stock and Other Ownership Interests - Abbvie |
Travel, Accommodations, Expenses - Abbvie |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Bayer; Celgene; Gilead Sciences; Incyte; Janssen; Novartis; Roche |
|
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Kite/Gilead; Novartis; Roche |